Website: N/A
Stock Symbol: NASDAQ: ACOR
Market Value: N/A (in millions)
We are a commercial-stage biopharmaceutical company dedicated to the
identification, development and commercialization of novel therapies that
improve neurological function in people with multiple sclerosis, or MS, spinal
cord injury, or SCI, and other disorders of the central nervous system, or CNS.
Our marketed product, Zanaflex Capsules, is approved by the U.S. Food and Drug
Administration (FDA) for the management of spasticity. Our lead product
candidate, Fampridine-SR, is in Phase 3 development for the improvement of
walking ability in patients with MS. In September 2006, we reported positive
Phase 3 clinical trial results from our first Phase 3 trial and we expect to
have results from our second Phase 3 trial of Fampridine-SR in the latter part
of the second quarter of 2008. If the results of this trial are favorable, we
intend to submit a New Drug Application (NDA) to the FDA in the first quarter of
2009.